Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and ...
Omeros Corporation is a biopharmaceutical company headquartered in Seattle, Washington, with a mission to develop first-in-class therapeutics for unmet medical needs. Founded in 1994 by Gregory A. Demopulos, MD, who continues to serve as CEO and Chairman, the company has evolved into a clinical-stage powerhouse with a diverse pipeline. Omeros ...Omeros Corporation is a biopharmaceutical company headquartered in Seattle, Washington, with a mission to develop first-in-class therapeutics for unmet medical needs. Founded in 1994 by Gregory A. Demopulos, MD, who continues to serve as CEO and Chairman, the company has evolved into a clinical-stage powerhouse with a diverse pipeline. Omeros went public on NASDAQ in 2009 under the ticker OMER, and its stock has experienced volatility, reflecting its clinical-stage nature.
The company's core focus is on the complement system, which is part of the immune system, and it has developed a leading asset, narsoplimab (OMS721), a monoclonal antibody targeting MASP-2. Narsoplimab has completed pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and is in Phase III trials for IgA nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), with a Phase II trial for COVID-19. This drug has the potential to address multiple serious conditions with high unmet need.
Beyond narsoplimab, Omeros has a rich pipeline including PPARγ (OMS405) for opioid and nicotine dependence, PDE7 (OMS527) for addiction and movement disorders, and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH). The company also conducts preclinical research on small-molecule MASP-2 inhibitors, next-generation antibodies, GPR174 inhibitors, and CAR T-cell therapies. Its research extends to G protein-coupled receptor targets across various disease areas.
Financially, Omeros is a biotech with high R&D expenses, reflected in its negative margins and cash burn. As of the latest data, it has a market cap of approximately $959 million, with a price-to-sales ratio of about 97, indicating high valuation relative to revenue. The company employs around 175 people and maintains a strong focus on innovation. While it has yet to achieve consistent profitability, its pipeline and scientific expertise position it for potential growth if its lead candidates succeed. With a strong intellectual property portfolio and a dedicated team, Omeros aims to transform patient care through next-generation therapeutics.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
+188.4%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-3.4M
+97.9%
-76.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
+6.1%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
+100.1%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
-91.8%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-116.2M
+22.0%
+128.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
+109.8%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
-197.3%
-74.0%
+66.7%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.76x
+63.8%
-35.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Afternoon, and welcome to today's earnings call for Omeros Corporation. After the company's remarks, we will conduct a question and answer session. If you would like to ask a question, please raise your hand. If you have dialed into today's call, please press 9 to raise your hand and 6 to unmute. Please be advised that this call is being recorded at the company's request and a replay will be available on the company's website. I will now turn the call over to Jennifer Williams, Investor Relations for Omeros. Please go ahead.
Gregory A. Demopulos: Thank you, and good afternoon, everyone. Before we begin, please note that today's discussion will include forward looking statements. These statements reflect management's current expectations and beliefs as of today and are subject to risks and uncertainties that could cause actual results to differ materially. For a detailed discussion of these risks and uncertainties, please refer to the special note regarding forward looking statements and the risk factors in our quarterly report on Form 10 Q filed today with the SEC as well as our most recent annual report on Form 10-K. Today's call also will include certain non GAAP financial measures. A reconciliation of these measures to the corresponding GAAP measures is included in Omeros' earnings release issued earlier today available on the Investor Relations page of our website and furnished with the form 8 k we filed today with the SEC. With that, I will turn the call over to Dr. Gregory Demopulos, Chairman and CEO of Omeros. Thank you, Jennifer, and good afternoon, everyone. Joining me today are David J. Borges, our chief accounting officer, Dr. Kathy Melfi, our chief regulatory officer, Dr. Steve Whitaker, vice president of clinical and Phil Woodman, our chief commercial officer. Promoted from within the company, Bill was recently appointed as our chief commercial officer and let me tell you a bit more about him. Bill joined Omeros 6 years ago as our vice president of sales and market development, bringing more than 25 years of industry experience, including sales and marketing leadership roles at Amgen, Spectrum Pharmaceuticals, and Jazz Pharmaceuticals. Where he led the global launch of defibrotide. Atomero's bill largely built our commercial team. And was instrumental in designing and executing the Yartemlia launch. I have long believed that Bill's background capabilities and achievements are ideally suited to Omeros' current and future objectives Under his leadership, our commercial team is driving Yartemlia toward becoming the standard of care for TA-TMA, and preparing for its expansion into a broad range of MASP 2 driven indications. Beyond complement, Bill's track record of driving growth across oncology, rare disease, and specialty biopharma products, will serve Omeros well. Before I turn to the financial details, let me highlight 3 points. First, Yartemlia generated $32.2 million in gross sales in its first full quarter on the …
